Imedex: Education is the Best Medicine®

QUICK POLL

If imatinib, nilotinib, and dasatinib are all approved for front-line therapy of newly diagnosed chronic phase (CP) chronic myelogenous leukemia (CML), what would you recommend as front-line therapy for a 42-year-old man who presents with high-risk CML by both the Sokal and Hasford (Euro) scoring systems and who has no matched sibling donor?

Announcements

INTERACTIVE CASE: COLON CANCER - ADJUVANT THERAPY AFTER RESECTED PRIMARY AND LIVER METASTASIS

Dr John Marshall describes a case of a patient who presents with an intact primary and solitary liver metastasis. He reviews the options for therapy and enlightens the participant about his preferred choices.

current controversies in the management of patients with high-risk colon cancer
contemporary treatment options for patients with metastatic colon cance
the use of molecular markers for screening and prognosis of colon cancer
the latest clinical trial results

Visit the newly enhanced E-Learning Center – now offering activities across expanded therapy areas with keyword search!

APPROACHING DEADLINES:

AUG 05	Abstract deadline	Perspectives in Melanoma XIV
19	Discounted Registration Deadline	Lymphoma & Myeloma 2010
23	Pre-registration deadline	16th Annual Perspectives in Breast Cancer
26	Pre-registration deadline	4th Asian Pacific Conference: Perspectives in Lung Cancer
Sept 03	Discounted Registration deadline	GASCO’s Annual Meeting & Best of ASCO
07	Abstract Submission Deadline	2010 Advances in Inflammatory Bowel Diseases/Crohn’s and Colitis Foundation’s Clinical & Research Conference
09	Pre-registration deadline	Perspectives in Melanoma XIV

PROMINENT ISSUES IN THE MANAGEMENT OF BREAST CANCER

Interact with expert faculty from leading cancer centers and academic institutions at The 16th Annual Perspectives in Breast Cancer, August 28 in New York City. The scientific agenda includes:

Clinical options for trastuzumab-resistant breast cancers
How to therapeutically approach ductal carcinoma in situ (DCIS)
“BRCAness” syndrome in women’s cancers
Use of anti-angiogenic therapy
Optimal duration of aromatase inhibitor therapy
Appropriate management of small cancers

Learn more

COMPLIMENTARY MEETING ON CHRONIC IMMUNE DISORDERS IN WOMEN

The Management of Women with Chronic Immune Disorders in the Era of Biologics is a one-day update designed for healthcare professionals with an interest in the treatment and management of women of all ages with chronic immune diseases such as inflammatory bowel disease, rheumatoid arthritis, and psoriasis. Agenda topics include healthcare maintenance, maintaining health and quality of life, and putting risk into perspective. Free to attend. September 25 in New York City.